{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:45:43Z","timestamp":1740167143750,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40120-020-00209-0","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T15:13:00Z","timestamp":1597158780000},"page":"605-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Maintenance Intravenous Immunoglobulin Treatment for Multiple Sclerosis Coexisting with Ehlers-Danlos Syndrome and Muir-Torre Syndrome: A Case Study"],"prefix":"10.1007","volume":"9","author":[{"given":"Srishti","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohnish","family":"Suri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-7585","authenticated-orcid":false,"given":"Cris S.","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"issue":"Suppl 2","key":"209_CR1","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1177\/135245850000602S05","volume":"6","author":"J Haas","year":"2000","unstructured":"Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler. 2000;6(Suppl 2):S18\u2013S20 (discussion S33).","journal-title":"Mult Scler"},{"issue":"5","key":"209_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","volume":"265","author":"EC Tallantyre","year":"2018","unstructured":"Tallantyre EC, Whittam DH, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265(5):1115\u201322.","journal-title":"J Neurol"},{"issue":"2","key":"209_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1352458510384496","volume":"17","author":"TL Vollmer","year":"2011","unstructured":"Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler. 2011;17(2):181\u201391.","journal-title":"Mult Scler"},{"issue":"1","key":"209_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2559.2009.03454.x","volume":"56","author":"SC Shalin","year":"2010","unstructured":"Shalin SC, Lyle S, Calonje E, et al. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56(1):133\u201347.","journal-title":"Histopathology"},{"key":"209_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2010.08.003","volume":"65","author":"MN Landis","year":"2011","unstructured":"Landis MN, Davis CL, Bellus GA, Wolverton SE. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. J Am Acad Dermatol. 2011;65:1054\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"209_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1385\/CRIAI:29:3:307","volume":"29","author":"S Tal","year":"2005","unstructured":"Tal S, Yehuda S. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clin Rev Allergy Immunol. 2005;29:307\u201310.","journal-title":"Clin Rev Allergy Immunol"},{"key":"209_CR7","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2147\/CMAR.S188172","volume":"11","author":"Q Xu","year":"2019","unstructured":"Xu Q, Zhang Z, Chen Z, et al. Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice. Cancer Manag Res. 2019;11:2073\u201385.","journal-title":"Cancer Manag Res"},{"key":"209_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","volume":"9","author":"PS Sorensen","year":"2002","unstructured":"Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing\u2013remitting multiple sclerosis: a meta-analysis. Eur J Neurol. 2002;9:557\u201363.","journal-title":"Eur J Neurol"},{"key":"209_CR9","first-page":"336","volume":"30","author":"A Olyaeemanesh","year":"2016","unstructured":"Olyaeemanesh A, Rahmani M, Goudarzi R, et al. Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Med J Islam Repub Iran. 2016;30:336.","journal-title":"Med J Islam Repub Iran"},{"key":"209_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1528-1157.1999.tb00742.x","volume":"40","author":"DE Jacome","year":"1999","unstructured":"Jacome DE. Epilepsy in Ehlers-Danlos syndrome. Epilepsia. 1999;40:467\u201373.","journal-title":"Epilepsia"},{"key":"209_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/archneur.57.1.123","volume":"57","author":"A Echaniz-Laguna","year":"2000","unstructured":"Echaniz-Laguna A, de Saint-Martin A, Lafontaine AL, et al. Bilateral focal polymicrogyria in Ehlers-Danlos syndrome. Arch Neurol. 2000;57:123\u20137.","journal-title":"Arch Neurol"},{"key":"209_CR12","first-page":"1","volume":"14","author":"J Vilisaar","year":"2007","unstructured":"Vilisaar J, Harikrishnan S, Suri M, Constantinescu CS. Ehlers-Danlos syndrome and multiple sclerosis: a possible association. Mult Scler. 2007;14:1\u20134.","journal-title":"Mult Scler"},{"key":"209_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/(SICI)1096-8628(19961211)66:2<239::AID-AJMG23>3.0.CO;2-T","volume":"66","author":"S Spranger","year":"1996","unstructured":"Spranger S, Spranger M, Kirchhof K. Ehlers-Danlos syndrome type VIII and leukodystrophy. Am J Med Genet. 1996;66:239\u201340.","journal-title":"Am J Med Genet"},{"key":"209_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1590\/S0100-879X2001000500007","volume":"34","author":"RA Sobel","year":"2001","unstructured":"Sobel RA. The extracellular matrix in multiple sclerosis: an update. Braz J Med Biol Res. 2001;34:603\u20139.","journal-title":"Braz J Med Biol Res"},{"key":"209_CR15","unstructured":"Gustafson A, Griswold B, Burchett ME, et al. Do abnormalities of extracellular matrix elements lead to autoimmune disorders? Unexpectedly high incidence of rheumatologic disorders in persons with Ehlers Danlos syndrome. In: Annual Meeting of the American Society of Human Genetics. New Orleans, Louisiana, 2006."},{"key":"209_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286418793766","volume":"11","author":"M Araki","year":"2018","unstructured":"Araki M, Lin Y, Ono H, et al. Application of immunotherapy for neurological manifestations in hypermobile Ehlers-Danlos syndrome. Ther Adv Neurol Disord. 2018;11:1\u20135.","journal-title":"Ther Adv Neurol Disord"},{"key":"209_CR17","first-page":"135","volume":"7","author":"S Frantz","year":"2002","unstructured":"Frantz S, Greiner A, Schoen C. A sebaceous tumor in a patient with acquired immunodeficiency syndrome. Eur J Med Res. 2002;7:135\u20137.","journal-title":"Eur J Med Res"},{"key":"209_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0190-9622(86)70273-9","volume":"15","author":"MS Stone","year":"1986","unstructured":"Stone MS, Duncan WC, McGavran MH. Torre's syndrome: exacerbation of cutaneous manifestations with immunosuppression. J Am Acad Dermatol. 1986;15:1001.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"209_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/1940-6207.CAPR-19-0528","volume":"13","author":"JG Mancuso","year":"2020","unstructured":"Mancuso JG, Foulkes WD, Pollak MN. Cancer immunoprevention: a case report raising the possibility of \u201cimmuno-interception\u201d. Cancer Prev Res. 2020;13(4):351\u20136.","journal-title":"Cancer Prev Res"},{"issue":"10","key":"209_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","volume":"21","author":"CR Garcia","year":"2019","unstructured":"Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol. 2019;21(10):1336\u2013422.","journal-title":"Clin Transl Oncol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-020-00209-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T14:06:42Z","timestamp":1712758002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-020-00209-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["209"],"URL":"https:\/\/doi.org\/10.1007\/s40120-020-00209-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}